Abivax Announces Results of its May 11, 2026 Annual General Meeting
Rhea-AI Summary
Abivax (Nasdaq:ABVX) held its annual general meeting of shareholders on May 11, 2026, chaired by Board Chair Sylvie Grégoire.
Shareholders approved all resolutions proposed by the Board, including 2025 financial statements, executive and director compensation policy, and delegations for financial transactions. Detailed voting results will be posted on Abivax's website.
Positive
- None.
Negative
- None.
News Market Reaction – ABVX
In the May 12 session, ABVX declined 0.61%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 05 | Royalty deal & offering | Positive | +5.7% | Repurchase of royalty certificates and $45M ADS offering at set price. |
| Apr 22 | Conference data plans | Positive | -2.6% | Announcement of nine obefazimod abstracts at Digestive Disease Week. |
| Apr 20 | AGM docs available | Neutral | -3.1% | Publication of preparatory documents and agenda for May 11 AGM. |
| Apr 01 | Regulatory filings | Positive | +3.0% | Filing of Universal Registration Document and Form 20-F with regulators. |
| Mar 23 | Full-year results | Negative | -4.5% | 2025 results with large net loss alongside strong cash position and updates. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has produced mixed reactions: capital markets and regulatory updates sometimes aligned positively with price, while clinical and financial disclosures saw both gains and pullbacks.
Over the past months, ABVX has focused on financing, regulatory reporting, and preparations for key shareholder and scientific events. A May 5, 2026 transaction combined a royalty certificate repurchase with a new ADS offering, which coincided with a positive price move. Earlier, the company announced upcoming obefazimod presentations, made AGM preparatory documents available for the May 11, 2026 meeting, and filed its 2025 financial and regulatory reports. The latest AGM results confirm shareholder approval of 2025 accounts, compensation policy, and financial transaction delegations, extending this governance trajectory.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Abivax Announces Results of its May 11, 2026 Annual General Meeting
PARIS, France – May 11, 2026 – 10:05 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on May 11, 2026 (the “General Meeting”), which was chaired by Ms. Sylvie Grégoire, Chair of the Board of Directors of Abivax (the “Board”).
The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2025 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board related to financial transactions.
Details of the vote results will be available on the Company’s website (www.abivax.com).
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878
Attachment
